APA (7th ed.) Citation

McGrail, D., Pilié, P., Rashid, N., Voorwerk, L., Slagter, M., Kok, M., . . . Lin, S. (2021). Reply to: 'Real-world prevalence across 159 872 patients with cancer supports the clinical utility of TMB-H to define metastatic solid tumors for treatment with pembrolizumab.' by D. Fabrizio et al. Annals of Oncology, 32(9), 1194. https://doi.org/10.1016/j.annonc.2021.06.017

Chicago Style (17th ed.) Citation

McGrail, D.J, et al. "Reply to: 'Real-world Prevalence Across 159 872 Patients with Cancer Supports the Clinical Utility of TMB-H to Define Metastatic Solid Tumors for Treatment with Pembrolizumab.' by D. Fabrizio Et al." Annals of Oncology 32, no. 9 (2021): 1194. https://doi.org/10.1016/j.annonc.2021.06.017.

MLA (9th ed.) Citation

McGrail, D.J, et al. "Reply to: 'Real-world Prevalence Across 159 872 Patients with Cancer Supports the Clinical Utility of TMB-H to Define Metastatic Solid Tumors for Treatment with Pembrolizumab.' by D. Fabrizio Et al." Annals of Oncology, vol. 32, no. 9, 2021, p. 1194, https://doi.org/10.1016/j.annonc.2021.06.017.